Urinary mutagenicity, CYP1A2 and NAT2 activity in textile industry workers

Journal of Occupational Health

Volumn 46, Issue 6, 2004, Pages 440-447

  Fanlo, Ana ^a   Sinués, Blanca ^a,b   Mayayo, Esteban ^a   Bernal, Luisa ^a   Soriano, Antonia ^a   Martínez Jarreta, Begoña ^a   Martínez Ballarín, Enrique ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

CYP1A2; NAT2; Textile workers; Urine mutagenicity

Indexed keywords

AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; BETA GLUCURONIDASE; CAFFEINE; CIGARETTE SMOKE; CYTOCHROME P450 1A2; DYE;

ACETYLATOR PHENOTYPE; ADULT; AEROBIC METABOLISM; AMES TEST; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DETOXIFICATION; HUMAN; MAJOR CLINICAL STUDY; MUTAGENICITY; OCCUPATIONAL EXPOSURE; SMOKING; STATISTICAL ANALYSIS; TEXTILE WORKER; URINE;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP1A2; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTAGENS; OCCUPATIONAL EXPOSURE; SMOKING; TEXTILE INDUSTRY;

NICOTIANA TABACUM; SALMONELLA TYPHIMURIUM;

EID: 10944241785     PISSN: 13419145     EISSN: None     Source Type: Journal    
DOI: 10.1539/joh.46.440     Document Type: Article

References (49)

1. International Agency for Research on Cancer. Chemicals, industrial processes and industries associated with cancer in humans. In: International Agency for Research on Cancer Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, France: International Agency for Research on Cancer, 1982: Vol. 1-29, Supple. 4, 31-34, 37-38, 166-167.
2. RM Hicks, R Wright and JS Wakefield: The induction of rat bladder cancer by 2-naphthylamine. Br J Cancer 46, 646-661 (1982)
3. P Vineis and L Simonato: Estimates of the proportion of bladder cancers attributable to occupation. Scand J Work Environ Health 12, 55-60 (1986)
4. CA Gonzalez, E Riboli and G Lopez-Abente: Bladder cancer among workers in the textile industry: results of a Spanish case-control study. Am J Indust Med 14, 673-680 (1988)
5. CA González, G López-Abente, MI Errezola, A Escolar, E Riboli, I Izarzugaza and M Nebot: Occupation and bladder cancer in Spain: a multicentre case-control study. Int J Epidemiol 18, 569-577 (1989)
6. S Mommsen and J Aagaard: Tobacco as a risk factor in bladder cancer. Carcinogenesis (Lond.) 4, 335-338 (1983)
7. International Agency for Research on Cancer. Tobacco smoking. In: International Agency for Research on Cancer Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, France: International Agency for Research on Cancer, 1986: Vol. 38.
8. FF Kadlubar: Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metabol Rev 26, 37-46 (1994)
9. FF Kadlubar, MA Butler, KR Kaderlik, HC Chou and NP Lang: Polymorphisms of aromatic amine metabolism in humans: relevance for humans carcinogenesis. Environ Health Persp 98, 69-74 (1992)
10. Kadlubar FF. Carcinogenic aromatic amine metabolism and DNA adduct detection in human. In: Ernster L, ed. Xenobiotics and Cancer. London: Taylor & Francis, 1991: 329-338.
11. DW Hein: Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948, 37-66 (1988)
12. S Mommsens and J Aagaard: Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett 32, 199-205 (1986)
13. J Hanke and B Krajewska: Acetylation phenotypes and bladder cancer. J Occup Med 32, 917-918 (1990)
14. JM Ladero, CK Kwok, C Jara, L Fernández, AM Silmi, D Tapia and AC Uson: Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 17, 96-99 (1985)
15. RA Cartwright, RW Gashan, HJ Rogers, RA Ahmad, DB Hall, E Higgins and MA Kahn: The role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2, 842-846 (1982)
16. H Bartsch, C Malaveille, M Friesen, FF Kadlubar and P Vineis: Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV. Molecular dosimetry studies implicates aromatic amines as bladder carcinogens. Eur J Cancer 8, 1199-1207 (1993)
17. B Sinués, J Pérez, ML Bernal, MA Sáenz, J Lanuza and M Bartolomé: Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res 52, 4885-4889 (1992)
18. Beland FA, Kadlubar FF. Factors involved in the induction of urinary bladder cancer by aromatic amines. In: Hoffman D, Harris CC, eds. Banbury Report 23. New aspects of tobacco carcinogenesis. New York: Cold Spring Harbor, 1986: 135-326.
19. KR Kardelik and FF Kadlubar: Metabolic polymorphisms and carcinogen-DNA adduct formation in human population. Pharmacogenetics 5, S108-S117 (1995)
20. MJ Stasik: Carcinomas of the urinary bladder in a 4-chloro-o-toluidine cohort. Int Arch Occup Environ Health 60, 21-24 (1988)
21. E Ward, A Carpenter, S Markowitz, D Roberts and W Halperin: Excess number of bladder cancer in workers exposed to ortho-toluidine and aniline. JNCI 83, 501-506 (1991)
22. P Møller and W HåKan: Genotoxic Hazards of azo pigments and other colorants related to 1-phenylazo-2-hydroxynaphthalene. Mutation Res 462, 13-30 (2000)
23. 2-Nitro-4-methylaniline. Toxikologiske Bewertung, Berufsgenossenschaft der chemischen industrie, Heidelberg 18, 15 (1995)
24. DM Grant, BK Tang and W Kalow: Variability in caffeine metabolism. Clin Pharmacol Ther 33, 591-602 (1983)
25. BK Tang, D Kadar, L Quian, J Iriah, J Yip and W Kalow: Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 46, 648-657 (1991)
26. MV Relling, JS Lin, GD Ayers and WE Evans: Racial and gender differences in N-acetyltransferase, xantine oxidase and CYP1A2 activities. Clin Pharmacol Ther 52, 643-658 (1992)
27. ME Campbell, SP Spielberg and W Kalow: A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42, 157-165 (1987)
28. C Kuenemann-Migcot, F Callais, J Momas and B Festy: Urinary promutagens of smokers: comparison of concentration methods and relation to cigarette consumption. Mutat Res 368, 141-147 (1996)
29. C Malaveille, G Brun, G Kolar and H Bartsch: Mutagenic and alkylating activities of 3-methyl-1-phenyltriazenes and their possible role as carcinogenic metabolites of the parent dimethyl compounds. Cancer Res 42, 1446-1453 (1982)
30. NY Kado, D Langley and E Eisenstadt: A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat Res 121, 25-32 (1983)
31. DM Maron and BN Ames: Revised methods for the Salmonella mutagenicity test. Mutat Res 113, 173-215 (1983)
32. K Falck, M Sorsa, H Vainio and I Kilpikari: Mutagenicity in urine of workers in rubber industry. Mutat Res 79, 45-52 (1980)
33. FF Kadlubar, LE Unruh, TJ Flammang, D Sparks, RK Mitchum and GJ Mulder: Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation and changes in biliary excretion. Chem Biol Interact 33, 129-147 (1985)
34. WW Weber and DW Hein: N-acetylation pharmacogenetics. Pharmacol Rev 37, 25-79 (1985)
35. FF Kadlubar, JA Miller and EC Miller: Hepatic microsomal N-glucuronidazion and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37, 805-814 (1977)
36. CY Wang, B Christensen, K Zukowski, KC Morton and MS Lee: Induction of DNA repair synthesis in human urothelial cells by the N-hydroxy metabolites of carcinogenic arylamines. J Natl Cancer Inst 72, 847-825 (1984)
37. RK Lynn, CT Garvie-Gould, DF Milam, KF Scott, CL Eastman, AM Ilias and RM Rogers: Disposition of the aromatic amines, benzidine in the rat: characterization of mutagenic urinary and biliary metabolites. Toxicol Appl Pharmacol 72, 1-14 (1984)
38. H Bartsch, N Caporaso, M Coda, F Kadlubar, C Malaville, P Skipper, G Talaska, SR Tannenbaun and P Vineis: Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 82, 1826-1831 (1990)
39. M Granella and E Clonfero: Sensitivity of different bacterial assays in detecting mutagens in urine of humans exposed to polycyclic aromatic hydrocarbons. Mutat Res 268, 131-137 (1992)
40. T Morita, Y Iwamoto, T Shimizu, T Masuzawa and Y Yanagihara: Mutagenicity tests with a permeable mutant of yeast on carcinogens showing false-negative in Salmonella assays. Chem Pharm Bull 37, 407-409 (1989)
41. JM Gentile, GJ Gentile and MJ Plewa: Mutagenicity of selected aniline derivatives to Salmonella following plant activation and mammalian hepatic activation. Mutat Res 188, 185-196 (1987)
42. DM DeMarini, LR Brooks, VK Bhatnagar and RB Hayes: Urinary mutagenicity as a biomarker in workers exposed to benzidine: correlation with urinary metabolites and urothelial DNA adducts. Carcinogenesis 18, 981-988 (1997)
43. J Lewalter and L Miksche: Individual variation and immunological effects in human biomonitoring. In: Garner RC, Farmer PB, Steel GT, Wright AS, eds. Human Carcinogen Exposure, Biomonitoring and Risk Assessment. Oxford: Oxford University Press, 1991: 315-327.
44. WW Weber, DW Hein, A Litwin and GM Lower: Relationship of acetylator status to isoniazid toxicity, lupus erythematosus and bladder cancer. FASEB J 42, 3086-3097 (1983)
45. J Brockmöller, I Cascorbi, R Kerb and I Roots: Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, gluthione S-transferases M1 and T1, microsomal epoxide hydrolasea and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56, 3915-3925 (1996)
46. SAJ Varizi, NC Hughes, H Sampson, G Darlington, MAS Jewett and DM Grant: Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics 11, 7-20 (2001)
47. S Pavanello, P Simioli, S Lupi, P Gregorio and E Clonfero: Exposure levels and cytochrome P4501A2 activity, but nor N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomark Prev 11, 998-1003 (2002)
48. Kadlubar FF, Butler MA, Hayes BE, Beland FA, Guengerich FP. Role of microsomal cytochromes P450 and prostaglandin H synthase in 4-aminobiphenyl-DNA- adduct formation. In: Miners J, Birket DJ, Drew R, McManus M, eds. Microsomes and drug oxidations. London: Francis and Taylor, 1988: 380-389.
49. ME Campbell, DM Grant, T Inaba and W Kalow: Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochromes (s) p-450 in human liver microsomes. Drug Metab Disp 15, 237-249 (1987)